Answers are grounded in this paper and cite their sources.
Methicillin-resistant Staphylococcus aureus (MRSA) causes intractable wound infections in which biofilms impede tissue repair. Curcumin (Cur) possesses antibacterial, anti-inflammatory and regenerative activities yet lacks specific targeting capacity. This work aimed to develop a biofilm-targeted curcumin conjugate for MRSA-infected wound therapy. Cur was conjugated to RNAIII-inhibiting peptide (RIP) through click chemistry. Cytotoxicity was evaluated in L929 fibroblasts; anti-biofilm performance was assayed against an MRSA strain, and a mouse full-thickness MRSA-infected wound model was used for in vivo assessment. RIP-Cur exhibited low cytotoxicity toward L929 cells. It inhibited MRSA biofilm formation by 71% and reduced the biomass of 48 h mature biofilms by 66.8%. In mouse wounds, RIP-Cur down-regulated pro-inflammatory and virulence factors and up-regulated healing-related markers, achieving improved wound-healing outcomes relative to the vancomycin group. This multifunctional RIP-Cur conjugate suppresses MRSA biofilm formation, modulates local inflammation and accelerates infected-wound tissue repair, supporting its potential as a candidate therapeutic agent for drug-resistant MRSA wound infections. Further work is required to fully dissect its complete mechanism of action and evaluate resistance-risk profiles.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: